Development of PK- and PBPK-based modeling tools for derivation of biomonitoring guidance values

There are numerous programs ongoing to analyze environmental exposure of humans to xenobiotic chemicals via biomonitoring measurements (e.g.: EU ESBIO, COPHES; US CDC NHANES; Canadian Health Measures Survey). The goal of these projects is to determine relative trends in exposure to chemicals, across time and subpopulations. Due to the lack of data, there is often little information correlating biomarker concentrations with exposure levels and durations. As a result, it can be difficult to utilize biomonitoring data to evaluate if exposures adhere to or exceed hazard/exposure criteria such as the Derived No-Effect Level values under the EU REACH program, or Reference Dose/Concentration values of the US EPA. A tiered approach of simple, arithmetic pharmacokinetic (PK) models, as well as more standardized mean-value, physiologically-based (PBPK) models, have therefore been developed to estimate exposures from biomonitoring results. Both model types utilize a user-friendly Excel spreadsheet interface. QSPR estimations of chemical-specific parameters have been included, as well as accommodation of variations in urine production. Validation of each model's structure by simulations of published datasets and the impact of assumptions of major model parameters will be presented.

[1]  F. Theil,et al.  Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. , 2001, Journal of pharmaceutical sciences.

[2]  Michael Wiese,et al.  Drug-membrane interactions : analysis, drug distribution, modeling , 2002 .

[3]  Conrad Brunk,et al.  Guidelines for the derivation of Biomonitoring Equivalents: report from the Biomonitoring Equivalents Expert Workshop. , 2008, Regulatory toxicology and pharmacology : RTP.

[4]  荒井保明 Pharmacokinetics , 1993 .

[5]  S Haddad,et al.  A methodology for solving physiologically based pharmacokinetic models without the use of simulation softwares. , 1996, Toxicology letters.

[6]  Edward Ohanian,et al.  Toxicokinetics and Risk Assessment , 2006 .

[7]  K Krishnan,et al.  Relative lipid content as the sole mechanistic determinant of the adipose tissue:blood partition coefficients of highly lipophilic organic chemicals. , 2000, Chemosphere.

[8]  Dale J Marino,et al.  Physiologically Based Pharmacokinetic Modeling Using Microsoft Excel and Visual Basic for Applications , 2005, Toxicology mechanisms and methods.

[9]  W. T. Berge,et al.  A generic, cross-chemical predictive PBTK model with multiple entry routes running as application in MS Excel; design of the model and comparison of predictions with experimental results. , 2011, The Annals of occupational hygiene.

[10]  George Loizou,et al.  Physiologically based pharmacokinetic modelling , 2003 .

[11]  Jerry L. Campbell,et al.  Quantitative interpretation of human biomonitoring data. , 2008, Toxicology and applied pharmacology.

[12]  M. Rowland,et al.  Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.

[13]  Ken Sexton,et al.  Human Biomonitoring of Environmental Chemicals , 2004 .

[14]  F. Theil,et al.  A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. , 2000, Journal of pharmaceutical sciences.

[15]  Reinhard Joas,et al.  Online integrated solution to collect data, generate information and manage events in the human biomonitoring field. , 2007, International journal of hygiene and environmental health.

[16]  Melvin E. Andersen,et al.  Physiologically Based Pharmacokinetic and Pharmacodynamic Modeling , 2004 .

[17]  C. T. Chiou,et al.  Partition coefficients of organic compounds in lipid-water systems and correlations with fish bioconcentration factors , 1985 .

[18]  Richard A. Corley,et al.  Physiologically Based Pharmacokinetics and the Dermal Absorption of 2-Butoxyethanol Vapor by Humans , 1997 .

[19]  Malcolm Rowland,et al.  Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[20]  Sean M Hays,et al.  Urinary DEHP metabolites and fasting time in NHANES , 2011, Journal of Exposure Science and Environmental Epidemiology.

[21]  Melvin E. Andersen,et al.  Physiologically Based Pharmacokinetic Modeling , 2010 .

[22]  Karthik Venkatakrishnan,et al.  Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models , 2001, Journal of clinical pharmacology.

[23]  Conrad Brunk,et al.  Guidelines for the communication of Biomonitoring Equivalents: report from the Biomonitoring Equivalents Expert Workshop. , 2008, Regulatory toxicology and pharmacology : RTP.

[24]  Michael S. Roberts,et al.  Physiologically based pharmacokinetics and pharmacodynamics of skin , 2008 .

[25]  D. Connell,et al.  Bioaccumulation of Xenobiotic Compounds , 1989 .

[26]  P ? ? ? ? ? ? ? % ? ? ? ? , 1991 .

[27]  J. Cocker,et al.  Exposure to the organophosphate diazinon: data from a human volunteer study with oral and dermal doses. , 2002, Toxicology letters.

[28]  D. Rick,et al.  Chlorpyrifos: pharmacokinetics in human volunteers. , 1984, Toxicology and applied pharmacology.

[29]  F. Gobas,et al.  Food Web–Specific Biomagnification of Persistent Organic Pollutants , 2007, Science.

[30]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[31]  Samuel P. Caudill,et al.  Urinary Creatinine Concentrations in the U.S. Population: Implications for Urinary Biologic Monitoring Measurements , 2004, Environmental health perspectives.

[32]  Ian Cousins,et al.  Development and application of a generalized physiologically based pharmacokinetic model for multiple environmental contaminants , 2003, Environmental toxicology and chemistry.

[33]  T. Mexia,et al.  Author ' s personal copy , 2009 .

[34]  A A Kousba,et al.  Physiologically based pharmacokinetic/pharmacodynamic model for the organophosphorus pesticide diazinon. , 2004, Neurotoxicology.

[35]  C Timchalk,et al.  A Physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[36]  Dana B Barr,et al.  Comparative pharmacokinetics of the organophosphorus insecticide chlorpyrifos and its major metabolites diethylphosphate, diethylthiophosphate and 3,5,6-trichloro-2-pyridinol in the rat. , 2007, Toxicology.

[37]  R A Corley,et al.  Physiologically based pharmacokinetics of 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in rats and humans. , 1994, Toxicology and applied pharmacology.

[38]  S Kezic,et al.  Free and total urinary 2-butoxyacetic acid following dermal and inhalation exposure to 2-butoxyethanol in human volunteers , 2004, International archives of occupational and environmental health.

[39]  Tye E Arbuckle,et al.  Reporting results of human biomonitoring of environmental chemicals to study participants: a comparison of approaches followed in two Canadian studies , 2010, Journal of Epidemiology & Community Health.

[40]  R A Becker,et al.  Biomonitoring equivalents: a screening approach for interpreting biomonitoring results from a public health risk perspective. , 2007, Regulatory toxicology and pharmacology : RTP.

[41]  Ludwine Casteleyn,et al.  Research on ethics in two large Human Biomonitoring projects ECNIS and NewGeneris: a bottom up approach , 2008, Environmental health : a global access science source.

[42]  Malcolm Rowland,et al.  Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes , 2007, Pharmaceutical Research.

[43]  K Krishnan,et al.  A biologically-based algorithm for predicting human tissue: blood partition coefficients of organic chemicals , 1995, Human & experimental toxicology.

[44]  Bruce H Alexander,et al.  Agreement of pesticide biomarkers between morning void and 24-h urine samples from farmers and their children , 2007, Journal of Exposure Science and Environmental Epidemiology.

[45]  L. A. Fenu,et al.  Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs , 2007, Drug Metabolism and Disposition.

[46]  J. Cocker,et al.  Biomonitoring at the UK Health and Safety Laboratory. , 2007, International journal of hygiene and environmental health.

[47]  Bruce A. Pearce,et al.  Windows® based general PBPK/PD modeling software , 2008, Comput. Biol. Medicine.

[48]  M. Rowland,et al.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.

[49]  Thomas Peyret,et al.  A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicals. , 2010, Toxicology and applied pharmacology.

[50]  M E Andersen,et al.  A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. , 1984, Toxicology and applied pharmacology.

[51]  Michael S. Roberts,et al.  Dermal Absorption and Toxicity Assessment , 2007 .

[52]  A. Leo,et al.  Partition coefficients and their uses , 1971 .

[53]  Dana B Barr,et al.  Characterizing children's exposures: beyond NHANES. , 2005, Neurotoxicology.